Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075444 | 0.82 | KDM4E (0.36) | KDM4ETDP1KMT2ALMNAHRH3 | |
| SCHEMBL25108944 | 0.81 | SIGMAR1 (0.42) | SIGMAR1 | |
| SCHEMBL10052292 | 0.81 | ARG1 (0.37) | SIGMAR1 | |
| SCHEMBL20648690 | 0.80 | GNAI3 (0.46) | KDM4ETDP1KMT2ALMNAHRH3 | |
| SCHEMBL26494063 | 0.80 | CYP2D6 (0.35) | KDM4ETDP1KMT2ALMNAHRH3 | |
| SCHEMBL15354330 | 0.80 | KDM1A (0.38) | HRH1SIGMAR1 | |
| SCHEMBL19606310 | 0.79 | KCNQ3 (0.34) | KDM4ETDP1KMT2ALMNAHRH3 | |
| SCHEMBL20850751 | 0.78 | KDM4E (0.37) | KDM4EKMT2AHTT | |
| SCHEMBL22963141 | 0.78 | KDM4E (0.37) | KDM4EKMT2AHTT | |
| SCHEMBL22794903 | 0.77 | HRH3 (0.39) | HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | KDM4E 2251/4885TDP1 2933/4885KMT2A 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.